Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Capozzi
Observed names:
Capozzi, Federica,
F. Capozzi
Institution:
Candiolo Cancer Institute
Observed institutions:
Ospedale Sant'Anna,
Istituto Ortopedico Rizzoli,
Ospedale Regina Margherita,
Candiolo Cancer Institute,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Fondazione Piemontese per la Ricerca sul Cancro Onlus,
University of Turin
show all 7
ORCID:
0000-0002-6458-5699
Observed ORCID:
0000-0002-6458-5699
OpenAlex ID:
A5027747604
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
2014
·
Giovanni Grignani
, Emanuela Palmerini
, et al.
·
The Lancet Oncology
·
360
PDF
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
2013
·
Ymera Pignochino
, Carmine Dell'Aglio
, et al.
·
Clinical Cancer Research
·
113
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
2017
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Molecular Cancer
·
75
PDF
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
2015
·
Ymera Pignochino
, Carmine Dell’Aglio
, et al.
·
BMC Cancer
·
38
PDF
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
2018
·
Giulia Mesiano
, Giovanni Grignani
, et al.
·
OncoImmunology
·
33
PDF
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
2020
·
Giulia Chiabotto
, Giovanni Grignani
, et al.
·
Cancers
·
32
PDF
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
2022
·
Alessandra Merlini
, Maria Laura Centomo
, et al.
·
Frontiers in Oncology
·
14
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes
2025
·
Giorgia Giordano
, Alessandra Merlini
, et al.
·
Cancer Immunology Immunotherapy
·
2
PDF
Abstract LB-213: The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS).
2013
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Cancer Research
·
1
Supplementary Table 1 from The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
2023
·
Ymera Pignochino
, Carmine Dell'Aglio
, et al.
PDF
Data from The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
2023
·
Ymera Pignochino
, Carmine Dell'Aglio
, et al.
Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).
2019
·
Giulia Chiabotto
, Maria Laura Centomo
, et al.
·
Journal of Clinical Oncology
Additional file 2: Figure S1. of PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
2017
·
Pignochino, Ymera
, Capozzi, Federica
, et al.
·
Figshare
Additional file 1: Table S1. of PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
2017
·
Pignochino, Ymera
, Capozzi, Federica
, et al.
·
Figshare
Abstract 3709: PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR)
2016
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Cancer Research
Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models of bone and soft tissue sarcoma (BSTS).
2014
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Journal of Clinical Oncology
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma
2013
·
Marco Basiric
, Federica Capozzi
, et al.
350 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas
2012
·
Y. Pignochino
, F. Capozzi
, et al.
·
European Journal of Cancer
Preclinical study of trabectedin (TR) and poly(ADP-ribose)polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS).
2012
·
Ymera Pignochino
, Federica Capozzi
, et al.
·
Journal of Clinical Oncology
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways
2012
·
Ymera Pignochino
, Carmine Dell'Aglio
, et al.
·
Cancer Research
PDF
Show more works
View as search
Works count:
25
Citation count:
668
H-index:
7
I10-index:
7
Year
Topic
Type